Product Name: PCTAIRE1 (173-179) pY176
Product Number: PE-04AJL85
Size: | 200 µg | | Price: | 35.00 |
| 1 mg | | $US | 71.00 |
| 5 mg | | | 153.00 |
Peptide Name: PCTAIRE1 (173-179) pY176
Product Use: Services as a blocking peptide for use with the PCTK1-pY176 rabbit polyclonal antibody (Cat. No.: AB-PK755) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain in subdomain I, which is involved in binding the phosphates in the ATP substrate. This is the major in vivo phosphorylation site in PCTK1. Y176 phosphorylation is predicted to be inhibitory for phosphotransferase activity.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: EGT-pY-ATV
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 993.94 Da
Peptide Purity Percent after Synthesis and Purification: >80
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: PCTAIRE1 - pY176 phosphosite-specific antibody (Cat. No.: AB-PK755) Scientific Background: PCTK1 (PCTAIRE1, CDK16) is a protein-serine/threonine kinase of the CMGC group and CDK family. It has an important role in vesicle trafficking. Specifically neuronal release of GH1 is mediated by PCTK1. It is also involved in spermatogenesis, dendrite development, neuronal differentiation, and insulin secretion. BRSK2 mediated phosphorylation of PCTK1 can be inhibited with aPCTK1S12A mutation, which leads to fully inhibited effect on insulin secretion. The interaction of PCTK1 and CCNY can be inhibited with a S119 phosphorylation and PCTK1 phosphotransferase activity can be constitutively activated through the mutation S153A. Interaction with CCNY can be inhibited with a S153D mutation. Phosphorylation at S119 induces interaction with 14-3-3 gamma and 14-3-3 zeta. Insertional mutagenesis studies in mice support a role for this protein kinase in mouse cancer oncogenesis.